 |
 Video: What is a Stock Split?
|
|
|
| Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, revumenib (SNDX-5613), and axatilimab (SNDX-6352). Co. is developing SNDX-5613, a small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia, and acute myeloid leukemia, or AML, and NPM1 mutant AML. Co. is also developing SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1, in chronic graft-versus-host disease, as well as idiopathic pulmonary fibrosis. According to our Syndax Pharmaceuticals stock split history records, Syndax Pharmaceuticals has had 0 splits. | |
|
Syndax Pharmaceuticals (SNDX) has 0 splits in our Syndax Pharmaceuticals stock split history database.
Looking at the Syndax Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Syndax Pharmaceuticals shares, starting with a $10,000 purchase of SNDX, presented on a split-history-adjusted basis factoring in the complete Syndax Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/03/2016 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$12.01 |
|
| End price/share: |
$20.74 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
72.69% |
|
| Average Annual Total Return: |
6.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$17,263.30 |
|
| Years: |
8.13 |
|
|
|
|
|
